Introduction
Several growth factors and their cognate receptor proteintyrosine kinases (RPTKs) control developmental pathways. let-23 is essential for Caenorhabditis elegans vulval development . Drosophila sevenless determines photoreceptor cell fate (Hafen et al., 1987) , whereas torso directs formation of anterior and posterior structures (Sprenger et al., 1989; Casanova and Struhl, 1989) . Murine hematopoiesis, melanogenesis, and gametogenesis require interaction between the steel gene product and its receptor c-Kit, encoded at the W locus (Pawson and Bernstein, 1990) .
A paradigm has emerged for RPTK signaling. Upon ligand binding, RPTKs dimerize, activate, and transphosphorylate on multiple tyrosines (Schlessinger and UIIrich, 1992) . Activated receptors transmit signals by recruiting secondary signaling molecules containing Src-homology 2 (SH2) domains, conserved stretches of about 100 amino acids that bind with high affinity to specific phosphotyrosine residues. Some secondary signaling proteins also have Src-homology 3 (SH3) domains, which bind to proline-rich peptide targets. SH2-and SH3-mediated interactions relocate enzymes such as phosphoinositide-3-kinase (PI3-kinase), phospholipase Cy, and Ras-GAP to their substrates, and/or increase their enzymatic activity (Koch et al., 1991 ; Schlessinger, 1994) . These events culminate in activation of pathways such as the Ras/Raf/mitogen-activated protein kinase (MAPK) cascade (Marshall, 1994) .
Several RPTK targets are required for normal development. sem-5 (Clark et al., 1992) , the homolog of Drosophila downstream of receptor kinases (drk) (Simon et al., 1993; Olivier et al., 1993) , mammalian GRB2 (Lowenstein et al., 1992) , and let-60 (Han et al., 1990) , a c-ras homolog, are required downstream of let-23. Likewise, Son ofsevenless (Sos), which encodes a Ras GTP/GDP exchange protein (Simon et al., 1991) , Rasl (Simon et al., 1991) , and rolled, a MAPK homolog (Brunner et al., 1994) , are essential for sevenless signaling.
Much less is known about protein-tyrosine phosphatase (PTP) function (Walton and Dixon, 1993) . The cloning of SH2-containing PTPs (SH-PTPs) suggested that these molecules might participate in the regulation of RPTK signaling (Neel, 1993) . Two vertebrate SH-PTPs sharing a similar protein structure (see Figure 1 ) consisting of two N-terminal SH2 domains, a PTP domain, and a C-terminus with phosphorylation sites have been described. SH-PTP1 (Plutzky et al., 1992) , also termed PTP1C (Shen et al., 1991) , HCP (Yi et al., 1992) , or SHP (Matthews et al., 1992) , is expressed mainly in hematopoietic cells. Its key role in hematopoiesis is illustrated by the finding that SH-PTP1 mutations cause the motheaten mouse (Tsui et al., 1993; Shultz et al., 1993) .
SH-PTP2 (Freeman et al., 1992) , also termed Syp , PTP1D (Vogel et al., 1993) , and PTP2C (Ahmad et al., 1993) , is expressed ubiquitously. It is the homolog of Drosophila corkscrew (csw) (Perkins et al., 1992) , which is required maternally as a positive signal transducer downstream of torso. Csw contains an insert of 150 amino acids within its PTP domain and lacks one of the two C-terminal tyrosine phosphorylation sites present within SH-PTP2. The biological significance of these differences has not been determined. Moreover, no role for SH-PTP2 in vertebrate development has been established.
Progress has been made in defining SH-PTP2 signaling pathways. SH-PTP2 associates with several activated RPTKs, including the platelet-derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR) Vogel et al., 1993; Lechleider et al., 1993b) as well as with the insulin receptor substrate IRS-1 (Kuhne et al., 1993) . Specific binding sequences for its SH2 domains have been defined in the PDGFR (Lechleider et al., 1993a; Kazlauskas et al., 1993; Feng et al., 1994) and IRS-1 (Sun et al., 1993; Case et al., 1994) , and a consensus binding sequence has been elucidated (Songyang et al., 1993; Case et al., 1994) . SH-PTP2 becomes tyrosine phosphorylated in response to PDGF and EGF Vogel et al., 1993; Lechleider et al., 1993b) . The sequences of the induced phosphorylation sites within the SH-PTP2 C-terminus suggested a mechanism for positive signaling in which tyrosine-phosphorylated SH-PTP2 recruits GRB2/ Sos to the activated PDGFR, thereby activating Ras (Li Bennett et al., 1994) . The role of the PTP domain in signaling has remained unclear. In addition, it is unclear how SH-PTP2 might participate in insulin signaling, since insulin does not stimulate SH-PTP2 tyrosine phosphorylation (Kuhne et al., 1993) .
In view of the function of csw, we asked whether SH-PTP2 is required for vertebrate development. The classic experiments of Nieuwkoop (1969) in Xenopus suggested that mesoderm arises as a result of inductive interactions between vegetal pole and animal pole cells. Much work has implicated peptide growth factors and their receptors in this process (Klein and Melton, 1994) . In the absence of growth factors, animal pole (ectodermal) explants of stage 8 Xenopus embryos (animal caps) undergo epidermal differentiation. Addition of members of the fibroblast growth factor (FGF) (e.g., bFGF) or transforming growth factor 13 (TGFI~) families (e.g., activin) to such explants can induce mesoderm. Both factors and their receptors are present in the early embryo (Klein and Melton, 1994) . A dominant negative mutant of a Xenopus FGF receptor blocks the effects of FGF on ectodermal explants and interferes with normal trunk and tail development (Amaya et al., 1991 (Amaya et al., , 1993 , whereas expression of a truncated activin receptor prevents formation of most, if not all mesoderm (Hemmati-Brivanlou and Melton, 1992) . Such studies implicate signaling by FGF and TGFI3 family members in early development in vivo.
To test the involvement of SH-PTP2 in mesoderm induction, we cloned Xenopus SH-PTP2, found that it is expressed maternally, and assayed the effects of injection of wild-type and various mutant SH-PTP2 RNAs on early development. An internal PTP domain deletion (AP) acted as a dominant negative mutant of SH-PTP2, resulting in severe posterior truncations. In animal caps, AP blocks FGF-and activin-mediated mesoderm induction. Furthermore, we show that SH-PTP2 acts upstream of MAPK in FGF receptor (FGFR) signaling.
Results

Cloning and Characterization of Xenopus SH-PTP2
If SH-PTP2 is involved in mesoderm induction, it must be supplied maternally, because zygotic transcription does not begin until after the mid-blastula transition (Newport and Kirschner, 1982b) . We molecularly cloned the Xenopus homolog of SH-PTP2 (XSH-PTP2) by sequential screening of cDNA libraries (see Experimental Procedures). We also cloned Xenopus SH-PTP1 (XSH-PTP1); the sequence of this clone will be reported elsewhere. Like human SH-PTP2 (HSH-PTP2), XSH-PTP2 contains two SH2 domains N-terminal to a consensus PTP domain as well as a C-terminal hydrophilic tail ( Figures 1A and 1 B) . HSH-PTP2 and XSH-PTP2 are 100%, 96%, 93%, and 88% identical through the N-terminal SH2 domain, C-terminal SH2 domain, PTP dcmain, and C-terminal tail, respectively; overall identity is 94%. XSH-PTP2 lacks an insert in its PTP domain. Both tyrosine phosphorylation sites present in the C-terminus of HSH-PTP2 are conserved in XSH-PTP2; only the more N-terminal of these sites is found in csw. The SH-PTP2 homologs all retain a proline-rich sequence comprising a potential SH3 binding site within their C-termini. These conserved structural components are likely to be important functionally. Northern analysis revealed that XSH-PTP2 RNA is present at similar levels maternally and zygotically ( Figure 1C ). SH-PTP2 protein was easily detected by immunoblot analysis in oocytes (Figure 1 D) and early embryos (see Figure 4D ; data not shown), consistent with the possibility that XSH-PTP2 is involved in early embryogenesis.
A Dominant Negative SH-PTP2 Mutant Alters Xenopus Embryonic Development
To probe the role of endogenous XSH-PTP2 in Xenopus embryos and to test the fun ction of various SH-PTP2 structural domains (specifically, the PTP domain and the C-terminal region), several altered HSH-PTP2 cDNAs were constructed ( Figure 2 ). We reasoned that SH-PTP2 molecules containing a PTP domain deletion (AP) and/or point mutations of its C-terminal tyrosines might act as dominant negative mutants. A PTP domain deletion was used, rather than a C-+S mutation of the essential catalytic cysteine (Guan and Dixon, 1991) , because C-+S mutants can sequester substrates (Bliska et al., 1992) . Thus, the effects of a C~S mutant might be more difficult to interpret. The mutations were introduced into HSH-PTP2 so that the injected product and endogenous XSH-PTP2 could be distinguished. Given the identity of the N-terminal SH2 domain and the strong conservation of the rest of the molecule, we were confident that HSH-PTP2 constructs would retain function within the Xenopus embryo. RNA synthesized from wild-type and mutant HSH-PTP2 plasmid constructs was injected into the dorsal marginal zone of 4-to 8-cell embryos. Embryos injected with water, full-length XSH-PTP2 ( Figures 3A and 3C ) or HSH-PTP2, or C-terminal Y--*F mutants (data not shown) developed normally (Figures 3A and 3C; Table 1 ). Embryos injected with AP RNA developed through the blastula stages and entered gastrulation normally, forming blastopore lips on their dorsal sides. However, they failed to complete gastrulation. Their blastopores remained open ( Figure 3B ), and as a result, the neural tube did not close and their tails were truncated in the early tadpole (stage 44) (compare Figures 3C and 3D ). Histological analysis confirmed that anterior development of AP embryos was normal (data not shown). Transverse sections revealed that mesodermal tissues were present and organized. However, at the midtrunk level, the notochord and neural tube were split. The somites were not duplicated and were generally found lateral to the notochord(s) ( Figures 3E and 3F ). This phenotype is similar to those produced by expression of dominant negative FGFR (Amaya et al., 1991) or dominant negative Raf (MacNicol et al., 1993) . The occurrence and severity of the phenotype were dependent on the dose of AP ( Figure 3G ). All subsequent experiments were performed at 5 ng/embryo.
We compared the expression of early mesodermal markers in embryos injected in the marginal zones of all four blastomeres at the 4-cell stage. In Xenopus, Brachyury (Xbra), Xwnt8, and goosecoid (gsc) are normally expressed throughout gastrulation (stage 12) (Dawid, 1991) . In agreement with previous work (Amaya et al., 1991 (Amaya et al., , 1993 , injection of dominant negative FGFR RNA blocks Xbra expression. AP also inhibits Xbra expression, whereas Xwnt8 and gsc levels are similar to controls (Figure 3H) .
Since immunoblotting revealed that RNAs from the C-terminal point mutant constructs were translated efficiently in injected embryos (data not shown), our results argue against these mutants acting as dominant negatives in Xenopus development (see below and Discussion). The similarity of the phenotype induced by AP injection to that caused by dominant negative FGFR RNA suggested that XSH-PTP2 might be a key component in FGF signaling. Therefore, we set out to determine the specificity of the AP effect.
Rescue of AP-Induced Defects by Expression of Wild-Type XSH-PTP2
We reasoned that AP is a dominant negative mutant that acts by binding, via its SH2 domains, to upstream regula- Embryos were injected with 2-5 ng of RNA at the 4-to 8-cell stage and scored for defects at stage 22. Embryos were coinjected at a 1:0.5 ratio (5 ng AP to 2.5 ng SH-PTP2 or SH-PTP1). % Other includes embryos with bifurcated tails or nonspecific abnormalities. An additional 16% displayed a less extreme condition wherein tail truncation was evident but the backs of the embryos fused (Table 1) . Both XSH-PTP2 ( Figure 4C ; Table 1) and HSH-PTP2 (data not shown) efficiently rescued the AP phenotype. Of 112 embryos coinjected with a 1:0.5 ratio of AP to XSH-PTP2 RNA, almost all (73%) developed completely normally; only a small fraction (6%) showed no evidence of rescue ( Figure 4C ; Table 1 ). Thus, increasing the amount of wild-type SH-PTP2 can overcome the developmental defects caused by AP. The AP phenotype was also rescued by SH-PTP2 RNA containing Y--*F mutations in both C-terminal tyrosine phosphorylation sites (data not shown). These data argue against the SH2 domains of AP sequestering upstream phosphotyrosine proteins indiscriminately. Since AP and HSH-PTP2 presumably differ only in that the former lacks PTP activity, PTP activity likely is required for SH-PTP2 signaling in early Xenopus development.
As a further test of specificity, we asked whether AP was also rescued by SH-PTP1. Injection of SH-PTP1 RNA into embryos over a wide range of concentrations had no effect upon early development (Table 1 ; data not shown). Moreover, coinjection of AP with XSH-PTP1 (or HSH-PTP1) did not rescue ( Figure 4B ). Failure to rescue was not due to absence of SH-PTP1 expression, as shown by immunoblotting. Our anti-SH-PTP1 antibodies do not cross-react with XSH-PTP1; hence, we could not rigorously show that XSH-PTP1 was expressed in coinjected embryos. However, we were able to detect full-length HSH-PTP1 protein easily ( Figure 4D ). Quantitative immunoblots using baculovirus-expressed HSH-PTP1 and HSH-PTP2 indicated that the anti-SH-PTP1 and anti-SH-PTP2 antibodies are comparably sensitive (data not shown). Whereas HSH-PTP2 efficiently rescues the AP phenotype ( Figure 4C ; Table 1 ), comparable amounts of HSH-PTP1 protein ( Figure 4D ) were completely ineffective ( Figure 4B ; Table 1 ). The anti-SH-PTP2 antibody is directed against the N-terminal SH2 domain (see Experimental Procedures). This domain is precisely conserved in Xenopus and human (see Figure 1) , so comparison of the intensity of the AP and endogenous XSH-PTP2 bands indicates their relative levels. Approximately a 5-fold excess of AP induced tail truncation. These data argue further against binding of AP SH2 domains to inappropriate targets and imply that the AP phenotype is due to specific interference with SH-PTP2.
probed with the indicated early mesodermal markers. Injection of either AP or FRD inhibits Xbra expression. The same blot rehybridized with a fibronectin probe (FN) serves as a control for RNA loading and integrity. 
Effects of SH-PTP2 Inhibition on Growth Factor Stimulation of Animal Caps
We also assayed the effect of AP on mesoderm induction in ectodermal explants (animal caps). Upon treatment with bFGF or activin, animal caps normally undergo extensive elongation. Injection of AP blocked FGF-induced animal cap elongation; XSH-PTP2 injection had no effect( Figures  5C and 5D ). Activin-induced elongation was also blocked by AP ( Figure 5G ). This may indicate that an intact FGF signaling pathway is required for activin action (LaBonne and Whitman, 1994; Cornell and Kimelman, 1994) , rather than direct participation of SH-PTP2 in activin signaling (see Discussion). One-to two-cell embryos were injected with AP or wild-type XSH-PTP2 RNA, then allowed to develop to stage 8. Animal caps were either left untreated (minus) or treated for 3 hr with 100 ng/ml bFGF (~olus F) or 5 ng/ml activin A (plus A), and RNA was prepared at stage 11. The resulting Northern blot was probed with the early marker Xbra and fibronectin (FN). Expression of these markers in total embryos (TE) is also shown. Injection of Ap RNA inhibits Xbra expression, whereas injection of wild-type XSH-PTP2 (WT) has no effect. Xbra expression is not detected in ~P-injected embryos even upon longer exposure of the blot.
(B) Inhibition of muscle actin expression. One-to two-cell embryos were injected with AP or wild-type XSH-PTP2 RNA, and animal caps, prepared at stage 8 as in (A), were either left untreated (minus) or treated for 3 hr with 100 ng/ml bFGF or 5 ng/ml activin A, as indicated. RNA prepared at stage 11 was used for Northern analysis with an actin probe. In both the uninjected and XSH-PTP2 RNA-injected lanes, induction of muscle-specific actin (arrow) is evident upon bFGF treatment. Ap injection blocks muscle actin induction. An analogous result is seen for activin-induced muscle actin expression. The actin probe cross-hybridizes with cytoplasmic actin (the two upper bands seen in both blots), which is not induced by either bFGF or activin A treatment, thus providing a control for RNA loading.
panied by defects in marker expression ( Figure 6 ). Elongation is accompanied by induction of early markers, such as Xbra (Smith et al., 1991) , and late markers, such as muscle-specific actin (Dworkin-Rastl et al., 1986) . Xbra induction by FGF or activin was decreased in AP-injected embryos, compared with uninjected controls ( Figure 6A ). FGF-and activin-stimulated expression of muscle-specific actin were also blocked in AP-injected animal caps; AP had no effect upon cytoplasmic actin expression, which serves as a loading control ( Figure 6B ).
SH-PTP2 Acts Upstream of MAPK
These data suggested that SH-PTP2 functions downstream from the FGFR in mesoderm induction. As in many RPTK signaling pathways (Marshall, 1994) , MAPK becomes activated upon bFGF addition to animal caps (LaBonne and Whitman, 1994; Graves et al., 1994; Hartley et al., 1994 of (or parallel to) MAPK. If SH-PTP2 acts upstream, Ap should block MAPK activation by bFGF, whereas if it is downstream (or parallel), MAPK activation should occur. We injected one-to two-cell embryos with Ap and allowed development to stage 8, Animal caps were prepared and dissociated in order to maximize cell exposure to bFGF (LaBonne and Whitman, 1994) . MAPK activation in Xenopus (Posada and Cooper, 1992) and other systems (Marshall, 1994 ) is due to phosphorylation on tyrosine and threonine residues and is marked by a mobility shift on SDS-polyacrylamide gels. MAPK from uninjected cells displayed the expected mobility shift in response to bFG F (Figure 7 ). However, in &P-injected cells, the lower mobility form did not appear, indicating that FGF failed to activate MAPK.
Discussion
We have cloned Xenopus SH-PTP2 and found that, like its Drosophila homolog csw (Perkins et al., 1992) (Klein and Melton, 1994) . Several lines of evidence support our contention that AP is a specific dominant negative mutant. Although over-expression of wild-type XSH-PTP2 or HSH-PTP2 alone has no effect, coinjection of either RNA efficiently rescues the AP phenotype. If the effects of ~P were due solely to expression of an excess of $H2 domains that gratuitously bind to multiple upstream phosphotyrosyl proteins, then coinjection of SH-PTP2 should potentiate the AP phenotype, because more SH2 domains would be available. Instead, our data are most consistent with competition between the SH2 domains of wild-type XSH-PTP2 and AP for a limited number of upstream targets; the balance between the two, and thus the ability of wild-type SH-PTP2 to rescue, can be altered by changing their relative levels of expression. Rescue of AP did not occur by competition for translation of the coinjected RNAs, and specificity of rescue is further supported by quantitative immunoblotting, which shows that AP levels roughly 5-fold higher than XSH-PTP2 are capable of producing the abnormal phenotype ( Figure 4D ; data not shown). Further evidence of specificity was provided by failure of the closely related XSH-PTP1 (or HSH-PTP1) to rescue, despite ample expression in injected embryos ( Figure 4D ). Together with the finding that SH-PTP1 mutations cause severe defects in hematopoiesis (Tsui et al., 1993; Shultz et al., 1993) in the presence of normal levels of SH-PTP2 (unpublished data), our data provide compelling genetic evidence that the two vertebrate SH-PTPs, despite similar structures, have distinct biological functions.
Injection of AP resulted in embryos with normal heads, but with dose-dependent severe tail truncations. Since gastrulation begins properly (normal involution of the dorsal blastopore lip), and the heads of these embryos develop normally ( Figures 3D and 4B ), SH-PTP2 probably is not required for formation of head mesoderm. Involution of lateral and ventral marginal zone cells did not go to completion in AP-injected embryos, leaving the blastopore open. This results in embryos with unfused backs in their posterior regions. Although mesodermally derived structures such as notochord and somites were evident in the grossly abnormal regions of AP embryos, analysis of early mesodermal markers by Northern blotting ( Figure 3H ) revealed that mesoderm formation is deficient. Overall, the AP phenotype is quite similar to that produced by dominant negative FGFR (Amaya et al., 1991 (Amaya et al., , 1993 or dominant negative Raf (MacNicol et al., 1993) , a downstream component of the FGF pathway.
Our data suggest a positive role for SH-PTP2 in FGF signaling. This notion is supported by the ability of AP to block the immediate effects of FGF (e.g., MAPK activation) in animal cap assays (Figure 7 ; see below). However, it is possible that SH-PTP2 is required for positive signaling from multiple RPTKs, which, combined with interference with the FGF pathway, leads to the observed tail truncation phenotype. We suspect that XSH-PTP2 does function in several growth factor signaling pathways, since recent work (L. Perkins, personal communication) indicates that csw is required for signaling in the Drosophila EGFR (torpedo), FGFR (breathless), and sevenless pathways. HSH-PTP2 (but not HSH-PTP1) efficiently complements csw in these pathways, strongly suggesting functional homology and implying that SH-PTP2 participates in multiple signaling pathways. Consistent with this hypothesis, SH-PTP2 physically interacts with multiple RPTKs in mammalian cells (see Introduction). Moreover, after submission of this manuscript, several groups reported that SH-PTP2 is required for positive signaling from the insulin receptor (Xiao et al., 1994; Milarski and Saltiel, 1994; Noguchi et al., 1994) . Although all available data in Drosophila, Xenopus, and mammals suggest that SH-PTP2 and its homologs are positive signaling elements, we cannot exclude a subsequent role for SH-PTP2 in termination of RPTK signals. Such a role could be obscured by blocking its positive signaling function.
Both activin-and bFGF-induced expression of Xbra and muscle-specific actin ( Figures 6A and 6B) were blocked in animal caps from AP-injected embryos. SH-PTP2 could be directly involved in both FGF and activin signaling. However, high level expression of a dominant negative FGFR blocks activin signaling, indicating that FGF may mediate part of the activin signal (LaBonne and Whitman, 1994; Cornell and Kimelman, 1994) . The apparent requirement for SH-PTP2 in activin signaling may be secondary to the role of SH-PTP2 in the FGF pathway.
Our data has several important implications for understanding SH-PTP2 signal transduction. Presumably, AP competes with XSH-PTP2for binding to an Upstream phosphotyrosyl protein(s). An obvious potential target is the XFGFR, since it contains a tyrosine matching the consensus binding site for the N-terminal SH2 domain of SH-PTP2 (Musci et al., 1990) . Although we see a substantial (5-to 10-fold) increase in tyrosine phosphorylation of SH-PTP2 when it is coinjected with wild-type FGFR (data not shown), suggesting SH-PTP2/FGFR interaction, we have been unable to demonstrate a direct physical association. This may be due to the limitations of our immunological reagents. However, it is also possible that the FGFR and SH-PTP2 do not stably associate; further experiments are required to resolve this issue.
Because an intact PTP domain is required for rescue of AP, we infer that PTP activity is required for positive signaling. Injection of a C~S mutant of HSH-PTP2 in its essential catalytic cysteine produces the same phenotype as AP (unpublished data), further supporting a positive role for PTP activity. Different domains of SH-PTP2 may be required for positive signaling in different pathways. Recent data in mammalian cells implicates the C-terminus of SH-PTP2 in PDGFR signaling (Li et al., 1994; Bennett et al., 1994) . Tyrosine phosphorylation within the SH-PTP2 C-terminus creates one or more binding sites for GRB2, suggesting that tyrosine-phosphorylated SH-PTP2 functions as an adapter to couple the PDGFR to Ras activation. However, there is no direct proof of the functional significance of these phosphorylation sites and/or of SH-PTP2/ GRB2 association. In addition, no data excludes a role for the PTP domain in the PDGFR pathway. The SH-PTP2 C-terminal Y-+F mutants did not affect early Xenopus embryo development and these mutants can rescue AP, indicating that tyrosine phosphorylation is not absolutely required for SH-PTP2 function. Tyrosine phosphorylation may be critical only in some pathways or may play a modulatory role that our assays cannot detect.
Finally, our results shed light on the likely position of SH-PTP2 in RPTK signaling pathways. The PTP domain requirement implies there must be an SH-PTP2 target(s) that becomes activated upon dephosphorylation. Attractive candidates are src family PTKs, which are negatively regulated by C-terminal tyrosine phosphorylation (Kmiecik and Shalloway, 1987; Cartwright et al., 1987; PiwnicaWorms et al., 1987) and which associate with some RPTKs (Kypta et al., 1990) . Alternatively, a novel tyrosine phosphoprotein(s) may be the target. The ability of Ap to block FGF-induced MAPK activation (Figure 7) positions SH-PTP2 downstream of the FGFR and upstream of MAPK. Our data on XSH-PTP2 are consistent with experiments on csw. Activated p21v'ras rescues the maternal-effect phenotypes of both torso and csw null mutations. This effect is dependent on Drosophila Raf activity (Lu et al., 1993) , placing csw downstream of torso, but upstream of Ras and Raf. Accordingly, microinjection of dominant negative Ras into Drosophila embryos produces a csw-like phenotype (Lu et al., 1993) . In mammalian cells, expression of catalytically inactive SH-PTP2 was reported to block insulin-induced MAPK induction (Milarski and Saltiel, 1994; Noguchi et al., 1994) and GTP loading of c-Ras (Noguchi et al., 1994) . All of these data suggest that SH-PTP2 lies upstream of Ras, at least in some signaling pathways. The relative position of SH-PTP2 and Ras in early Xenopus development may be more complex. In Xenopus embryos, microinjection of high concentrations of p21v-~" produces cell cycle arrest (Daar et al., 1991) and MAPK activation (unpublished data). Injection of lower amounts of p21 .... results in mesoderm induction (Whitman and Melton, 1989) . Coinjection of AP fails to block either Ras-induced cell cycle arrest or MAPK activation (unpublished data). Likewise, AP does not extinguish mesoderm induction produced by p21v-r% although preliminary experiments suggest that there may be a decrease in the total mass of mesoderm in coinjected embryos. A possible explanation for this complexity is provided by recent evidence for an FGF autocrine loop in early Xenopus embryos (Isaacs et al., 1994) . Such a loop could make SH-PTP2 appear to be both upstream and downstream of p21 v-r~. Further experiments are required to elucidate the direct targets of SH-PTP2 action and to clarify how these targets lead to MAPK activation.
Experimental Procedures
Full-Length Constructs XSH-PTP2 was isolated by low stringency hybridization of randomprimed full-length HSH-PTP2 to 1 x 106 plaques of a XZAPII stage 17 cDNA library (Thomsen et al., 1990) . Hybridizations were performed in 20% formamide, 6 x SSC, and 1% SDS. Washes were carried out in 2 x SSC, 0.1% SDS twice for 30 min at room temperature, followed by 0.2x SSC, 0.1% SDS twice for 30 rain at 42°C. Plasmids were recovered from purified plaques by superinfection with single-strand helper phage, as per the instructions of the manufacturer (Stratagene). One partial clone was used to screen a Zgtl0 Xenopus oocyte cDNA library (Rebagliati et al., 1965) . Inserts from isolated plaques were subcloned into pBlueScript (Stratagene) by polymerase chain reaction (PCR) using Vent polymerase (New England Biolabs) or by restricting isolated phage DNA with EcoRI. Subcloned inserts were sequenced on both strands on a 373A DNA sequencer (Applied Biosystems, Inc.). DNA and amino acid sequences were analyzed using BLAST (Altschul et al., 1990) or the Genetics Computer Group programs (Devereux et al., 1984) .
Mutant Construction
A 93 nucleotide in-frame deletion in the HSH-PTP2 PTP domain was made by PCR-generated overlap extension (Innis et al., 1990) . Using the primers 5'-GCACCATAAGCTTGAGAGCATC-3' and 5'-GATGCTC-TCAAGCTTATGGTGC-3', a Hindlll restriction site was introduced by each primer during amplification of the N-terminal and C-terminal fragments: PCRcgenerated products were digested with Hindlll and EcoRI, then cloned via three-way ligation into pSP64RI (see below) linearized with EcoRl. The resultant protein lacks 31 amino acids (amino acids 446-476) including the essential catalytic VHCSAG motif (Guan and Dixon, 1991) . Single and double Y~F mutants of HSH-PTP2 C-terminal tyrosines have been described .
Plasmid Constructs and In Vitro Transcriptions
For in vitro transcription, SH-PTP2 constructs were inserted into the modified pSP64T (Krieg and Melton, 1984) vector pSP64RI (S. Sokol, unpublished data), which contains a polylinker flanked by Xenopus [~-globin 5' and 3' untranslated sequences. Xenopus FGFR constructs (Amaya et al., 1991) were from E. Amaya. In vitro transcription of linearized plasmids was carried out using SP6 polymerase and the MEGAscript kit (Ambion).
Embryo Manipulations
Fertilization and embryo culture in 0.1 x MMR were performed as described (Newport and Kirschner, 1982a) . Embryos were transferred to 0.5x MMR, 3% Ficoll (Sigma) and injected with 10 nl of 0.5-1 rag/ ml RNA. For animal cap assays, embryos were injected in the animal pole at the 1-2 cell stage. To assay whole embryos, injections in the dorsal marginal zone were performed on pigmented embryos that showed a clear dorsal-ventral axis at the 4-cell stage. Embryos were transferred to 0.1 x MMR and allowed to develop at room temperature for 4-5 hr. Staging was according to Nieuwkoop and Faber (1967) . Embryonic explants were fixed in 0.75 x PBS plus 3.7% formaldehyde for I hr at room temperature, and histological analysis was performed as described (Sokol et al., 1990) .
Animal caps were excised from midblastulae (stage 8-8.5) and cultured in low calcium medium (Itoh and Sokol, 1994) with or without growth factors until stage 11. Explants were cultured further in 0.7 x MMR or lysed for early marker analysis. Recombinant human bFGF (GIBCO) was used at 60-100 ng/ml and recombinant human activin A (Itoh and Sokol, 1994) at 5 ng/ml.
RNA and Protein Analysis
RNA extraction and Northern analysis of early and late markers was performed as described (Itoh and Sokol, 1994) . Animal caps dissociated in calcium-free, magnesium-free normal amphibian media (Green and Smith, 1990) were either left untreated or treated with 100 ng/ml bFGF for 5 rain, pelleted, and frozen. These were lysed in oocyte lysis buffer (250 mM sucrose, 100 mM NaCI, 2.5 mM MgCI2, 10 mM NaF, 10 mM EGTA, 1 mM Na3VO4, 20 mM HEPES [pH 7.2], and 10/0 Triton X-100) containing protease inhibitors (10 i~g/ml leupeptin, 1 i~g/ml aprotinin, 1 I~g/ml pepstatin A, 1 i~g/ml antipain, and 20 I~g/ml phenylmethylsulfonyl fluoride), clarified at 13,000 rpm for 5 min at 4°C, electrophoresed, and blotted onto Immobilon P (Millipore). Total protein was prepared from manually defolliculated stage VI oocytes by similar procedures.
Sf9 cells were infected with HSH-PTP2 baculovirus, incubated for two days at 27°C, and lysed in NP-40 buffer (Lechleider et al., 1993b) . Construction and characterization of the virus will be described elsewhere. Soluble lysates were quantitated by BCA assay (Pierce), resolved by SDS-PAGE, and transferred onto Immobilon P. Immunoblots were probed with C-terminal anti-Xenopus MAPK rabbit polyclonal antibodies (Hartley et al., 1994) , rabbit antibodies against HSH-PTP1 (Lorenz et al., 1994) , or mouse monoclonal anti-PTP1D/ SH-PTP2 antibody (Transduction Laboratories), incubated with either anti-mouse-or anti-rabbit-horseradish peroxidase secondary antibodies and developed by enhanced chemiluminescence (ECL; Amersham).
